SECONDARY HYPERPARATHYROIDISM-CHRONIC KIDNEY DISEASE

Clinical trials for SECONDARY HYPERPARATHYROIDISM-CHRONIC KIDNEY DISEASE explained in plain language.

Never miss a new study

Get alerted when new SECONDARY HYPERPARATHYROIDISM-CHRONIC KIDNEY DISEASE trials appear

Sign up with your email to follow new studies for SECONDARY HYPERPARATHYROIDISM-CHRONIC KIDNEY DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1 Terminated 1

New Dual-Target drug aims to beat current therapy for kidney Patients' hormone problem

Disease control Recruiting now

This Phase 3 trial tests a new drug called MT1013 against an existing drug, cinacalcet, in 424 adults on dialysis who have secondary hyperparathyroidism (overactive parathyroid glands). The study aims to see if MT1013 better controls parathyroid hormone levels and improves bone h…

Matched conditions: SECONDARY HYPERPARATHYROIDISM-CHRONIC KIDNEY DISEASE

Phase: PHASE3 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 07:52 UTC

SECONDARY HYPERPARATHYROIDISM-CHRONIC KIDNEY DISEASE

Get alerted when new SECONDARY HYPERPARATHYROIDISM-CHRONIC KIDNEY DISEASE trials appear

New Dual-Target drug aims to beat current therapy for kidney Patients' hormone problem